SEARCH

SEARCH BY CITATION

References

  • 1
    Gennigens C,Menetrier-Caux C,Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58: 12445.
  • 2
    Roddam AW,Allen NE,Appleby P,Key TJ,Ferrucci L,Carter HB,Metter EJ,Chen C,Weiss NS,Fitzpatrick A,Hsing AW,Lacey JV,Jr, et al. Insulin-like growth factors. Their binding proteins and prostate cancer risk: analysis of individual patient data from 12 prospective Studies. Ann Intern Med 2008; 149: 46171.
  • 3
    Morris JK,George LM,Wu T,Wald NJ. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 2006; 95: 11217.
  • 4
    Renehan AG,Zwahlen M,Minder C,O'Dwyer ST,Shalet SM,Egger M. Insulin-like growth factor (IGF)-I. IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 134653.
  • 5
    Shi R,Berkel HJ,Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001; 85: 9916.
  • 6
    Juul A,Dalgaard P,Blum WF. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 253442.
  • 7
    Perk H,Serel TA,Delibas N,Sutcu R. Prostatic fluid-free insulin-like growth factor-1 in relation to prostate cancer. BJ U Int 2001; 88: 9469.
  • 8
    Chene G,Thompson SG. Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 1996; 144: 61021.
  • 9
    Greenland S,Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 13019.
  • 10
    Lacey JV,Jr,Hsing AW,Fillmore CM,Hoffman S,Helzlsouer KJ,Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 2001; 10: 11012.
  • 11
    Kanety H,Madjar Y,Dagan Y,Levi J,Papa MZ,Pariente C,Goldwasser B,Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77: 22933.
  • 12
    Harris RJ,Bradburn MJ,Deeks JJ,Harbord RM,Altman DG,Sterne JAC. Metan: fixed- and random-effects meta-analysis. Stata J 2008; 8: 328.
  • 13
    DerSimonian R,Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 188.
  • 14
    Higgins JPT,Thompson SG,Deeks JJ,Altman D. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 55760.
  • 15
    Egger M,Davey Smith G,Schneider M,Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 62934.
  • 16
    Begg CB,Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088101.
  • 17
    Stattin P,Rinaldi S,Biessy C,Stenman UH,Hallmans G,Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004; 22: 310412.
  • 18
    Shariat SF,Lamb DJ,Kattan MW,Nguyen C,Kim J,Beck J,Wheeler TM,Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002; 20: 83341.
  • 19
    Ho PJ,Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 1997; 46: 33342.
  • 20
    Juni P,Altman DG,Egger M. Assessing the quality of controlled clinical trials. Br Med J 2001; 323: 426.
  • 21
    Gregorio DI,Kulldorff M,Sheenan J,Samociuk H. Geographic distribution of prostate cancer incidence in the era of PSA testing. Connecticut, 1984 to 1998. Urology 2004; 63: 7882.
  • 22
    Rinaldi S,Kaaks R,Zeleniuch-Jacquotte A,Arslan AA,Shore RE,Koenig KL,Dossus L,Riboli E,Stattin P,Lukanova A,Toniolo P. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prevent 2005; 14: 4852.
  • 23
    Kehinde EO,Akanji AO,Mojiminiyi OA,Bashir AA,Daar AS,Varghese R. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer Prostatic Dis 2005; 8: 8490.
  • 24
    Aksoy Y,Aksoy H,Bakan E,Atmaca AF,Akcay F. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int 2004; 72: 625.
  • 25
    Allen N,Key T,Appleby PN,Travis R,Roddam A,Rinaldi S,Egevad L,Rohrmann S,Linseisen J,Pischon T,Boeing H,Johnsen NF, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the Eruopean prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prevent 2007; 16: 11217.
  • 26
    Baffa R,Reiss K,El-Gabry EA,Sedor J,Moy ML,Shupp-Byrne D,Strup SE,Hauck WW,Baserga R,Gomella LG. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech Urol 2000; 6: 2369.
  • 27
    Chan JM,Stampfer MJ,Giovannucci E,Gann PH,Ma J,Wilkinson P,Hennekens CH,Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 5636.
  • 28
    Chen C,Lewis SK,Voigt L,Fitzpatrick A,Plymate SR,Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005; 103: 7684.
  • 29
    Chokkalingam AP,Pollak M,Fillmore CM,Gao YT,Stanczyk FZ,Deng J,Sesterhenn IA,Mostofi FK,Fears TR,Madigan MP,Ziegler RG,Fraumeni JF,Jr, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 4217.
  • 30
    Cohen P,Peehl DM,Stamey TA,Wilson K,Clemmons D,Rosenfeld R. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 10315.
  • 31
    Cutting CW,Hunt C,Nisbet JA,Bland JM,Dalgleish AG,Kirby RS. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer.[see comment]. BJ U Int 1999; 83: 9969.
  • 32
    Djavan B,Bursa B,Seitz C,Soeregi G,Remzi M,Basharkhah A,Wolfram R,Marberger M. Insulin-like growth factor 1 (IGF-1). IGF-1 density, and. IGF-1/PSA ratio for prostate cancer detection. Urology 1999; 54: 6036.
  • 33
    Finne P,Auvinen A,Koistinen H,Zhang WM,Maattanen L,Rannikko S,Tammela T,Seppala M,Hakama M,Stenman UH. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000; 85: 27447.
  • 34
    Harman SM,Metter EJ,Blackman MR,Landis PK,Carter HB. Baltimore longitudinal study on aging: serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 425865.
  • 35
    Hazem IA,Pollak M,Behlouli H,Tanguay S,Begin LR,Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. J Urol 2002; 168: 242630.
  • 36
    Hernandez W,Grenade C,Santos ER,Bonilla C,Ahaghotu C,Kittles RA. IGF-I and IGFBP-3 gene variantes influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 2007; 28: 21549.
  • 37
    Hill M,Bilek R,Safarik L,Starka L. Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate. Physiol Res 2000; 49 ( Suppl 1): S11318.
  • 38
    Janssen JA,Wildhagen MF,Ito K,Blijenberg BG,Van Schaik RH,Roobol MJ,Pols HA,Lamberts SW,Schroder FH. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 2004; 89: 43916.
  • 39
    Khosravi J,Diamandi A,Mistry J,Scorilas A. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001; 86: 6949.
  • 40
    Koliakos G,Chatzivasiliou D,Dimopoulos T,Trachana V,Paschalidou K,Galiamoutsas V,Triantos A,Chitas G,Dimopoulos A,Vlatsas G. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Dis Markers 2000; 16: 1436.
  • 41
    Kurek R,Tunn UW,Eckart O,Aumuller G,Wong J,Renneberg H. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJ U Int 2000; 85: 1259.
  • 42
    Li L,Yu H,Schumacher F,Casey G,Witte JS. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003; 14: 7216.
  • 43
    Lopez JB,Sahabudin RM,Chin LP. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer? Int J Biol Markers 2004; 19: 1647.
  • 44
    Mantzoros C,Tzonou A,Signorello LB,Stampfer M,Trichopoulos D,Adami H-O. Insulin-like growth factor in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 111518.
  • 45
    Marszalek M,Wachter J,Ponholzer A,Leitha T,Rauchenwald M,Madersbacher S. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Eur Urol 2005; 48: 349.
  • 46
    Meyer F,Galan P,Douville P,Bairati I,Kegle P,Bertrais S,Czernichow S,Hercberg S. A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomarkers Prev 2005; 14: 226972.
  • 47
    Miyata Y,Sakai H,Hayashi T,Kanetake H. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003; 54: 12532.
  • 48
    Nam RK,Trachtenberg J,Jewett MA,Toi A,Evans A,Emami M,Narod SA,Pollak M. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 12703.
  • 49
    Oliver SE,Gunnell D,Donovan J,Peters TJ,Persad R,Gillatt D,Pearce A,Neal DE,Hamdy FC,Holly J. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004; 108: 887892.
  • 50
    Peng L,Tang S,Xie J,Luo T,Dai B. Quantitative analysis of IGF-1 and its application in the diagnosis of prostate cancer (Chinese). Hua Hsi I Ko Ta Hsueh Hsueh Pao 2002; 33: 1379.
  • 51
    Platz EA,Pollak MN,Leitzmann MF,Stampfer MJ,Willett WC,Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005; 16: 25562.
  • 52
    Schaefer C,Friedman GD,Quesenberry CP,Orentreich N,Vogelman JH. IGF-I and prostate cancer. Science 1998; 282: 199a.
  • 53
    Scorilas A,Plebani M,Mazza S,Basso D,Soosaipillai AR,Katsaros N,Pagano F,Diamandis EP. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 2003; 54: 2209.
  • 54
    Severi G,Morris HA,MacInnis RJ,English DR,Tilley WD,Hopper JL,Boyle P,Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 113741.
  • 55
    Trapeznikova MF,Shibaeva AN,Ianshin AA,Urenkov SB,Mironova OS,Kazantseva IA,Kushlinski NE. Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer (Russian). Urologiia 2004; 1721.
  • 56
    Weiss JM,Huang W-Y,Rinaldi S,Fears TR,Chatterjee N,Chia D,Crawford ED,Kaaks R,Hayes RB. IGF-I and IGFBP-3: risk of prostate cancer among men in the prostate. Lung colorectal and ovarian cancer screening trial. Int J Cancer 2007; 121: 226773.
  • 57
    Wolk A,Mantzoros CS,Andersson SO,Bergstrom R,Signorello LB,Lagiou P,Adami HO,Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.[see comment]. J Natl Cancer Inst 1998; 90: 91115.
  • 58
    Woodson K,Tangrea JA,Pollak M,Copeland TD,Taylor PR,Virtamo J,Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003; 63: 39914.
  • 59
    Zhigang Z,Jieming L,Wenlu S. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0–10.0 ng/ml. J Surg Oncol 2007; 96: 5461.
  • 60
    Trojan L,Bode C,Weiss C,Mayer D,Grobholz R,Alken P,Michel MS. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Eur Urol 2006; 49: 28692.
  • 61
    Signorello LB,Brismar K,Bergstrom R,Andersson SO,Wolk A,Trichopoulos D,Adami HO. Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst 1999; 91: 19657.
  • 62
    Stattin P,Bylund A,Rinaldi S,Biessy C,Dechaud H,Stenman UH,Egevad L,Riboli E,Hallmans G,Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 191017.
  • 63
    Freedland SJ,Sokoll LJ,Platz EA,Mangold LA,Bruzek DJ,Mohr P,Yiu SK,Partin AW. Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 2005; 174: 126670.
  • 64
    Pollak M,Beamer W,Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998; 17: 38390.
  • 65
    Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev 2001; 23: 5966.
  • 66
    Nickerson T,Chang F,Lorimer D,Smeekens SP,Sawyers CL,Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61: 627680.
  • 67
    Yakar S,LeRoith D,Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 2005; 16: 407420.
  • 68
    Berrigan D,Potischman N,Dodd KW,Nicar M,McQuillan G,Lavigne JA,Barrett JC,Ballard-Barbash R. Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum. Cancer Epidemiol Biomarkers Prev 2007; 16: 101722.
  • 69
    Inman BA,Harel F,Audet JF,Meyer F,Douville P,Fradet Y,Lacombe L. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 2005; 47: 695702.
  • 70
    Holly J,Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006; 83: 154160.
  • 71
    Ito Y,Nakachi K,Imai K,Hashimoto S,Watanabe Y,Inaba Y,Tamakoshi A,Yoshimura T. Stability of frozen serum levels of insulin-like growth factor-i, insulin-like growth factor-ii, insulin-like growth factor binding protein-3, transforming growth factor? Soluble Fas and superoxide dismutase activity for the JACC study. J Epidemiol 2005; 15: S6773.
  • 72
    Khosravi J,Diamandi A,Bodani U,Khaja N,Krishna RG. Pitfalls of immunoassay and sample for IGF-1: comparison of different assay methodologies using various fresh and stored serum samples. Clin Biochem 2005; 38: 65966.
  • 73
    Yu H,Nicar MR,Shi R,Berkel HJ,Nam R,Trachtenberg J,Diamandis EP. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001; 57: 4715.
  • 74
    Wald NJ,Hackshaw AK,Frost CD. When can a risk factor be used as a worthwhile screening test? Br Med J 1999; 319: 15625.
  • 75
    Oliver SE,Holly J,Peters TJ,Donovan J,Persad R,Gillatt D,Pearce A,Hamdy FC,Neal DE,Gunnell D. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology 2004; 64: 31722.
  • 76
    Juul A,Scheike T,Davidsen M,Gyllenborg J,Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 93944.
  • 77
    Thissen J-P,Ketelslegers J-M,Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80101.